ProMetic Life Sciences Inc. (PLI) 2013年年度报告「TSX」.pdf

1、ANNUAL REPORT 2013We care about -D13096Table of ContentExecutive Summary 1ProMetic 2Significant Events 3Message to Shareholders 4Proteins and Therapeutics 6MD&A 14Financial Statements 33Management Team and Board of Directors 71Corporate Information 721PROMETIC LIFE SCIENCES INC.The Corporation,on th

2、e back of its strengthening market capitalization,took the strategic decision to develop more of its assets to an advanced stage prior to partnering.This has allowed ProMetic to retain a greater portion of the future returns from those high-value products and lucrative markets,thereby ultimately inc

3、reasing shareholder value.This change to the commercialization strategy,manifested itself,in the short term,in lower than anticipated service and licensing revenues from third par-ties as well as an increase in spending.Accordingly,ProMetic improved its finan-cial position during 2013 by successfull

4、y raising over$30 million in debt and equity via two separate financial transactions and through the receipt of the Hepalink investment.Early in the year,ProMetic announced it had finalized a$10 million strategic equity investment by Shenzhen Hepalink Pharmaceutical Co.,LTD.(“Hepalink”)at a premium

5、to market share price.Dur-ing the third quarter,the Corporation secured$10 million by way of a debt financing transaction with Thomvest Seed Capital Inc.Lastly,during the last quarter of 2013,the Corporation closed a common share offering and issued a total of 26,651,400 shares for total gross proce

6、eds of$23,986,260 as part of that equity offering.With this strengthened balance sheet,ProMetic can now concentrate its atten-tion on further progressing its key corpor-ate initiatives necessary in building sub-stantial value for shareholders.ProMetic shall continue to generate product and service r